Entrada Therapeutics Inc Dossier - Source-backed chat

Entrada Therapeutics Inc

TRDANASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.17

Intrinsic Value $6.91median of 2 methodsbased on filings through 30 Jun 2026

Market Price $5.68Price as of 1 Oct 2026

UndervaluedIntrinsic value is 22% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $221.2M

Enterprise Value $121.9M

Shares Outstanding 42.2M diluted

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Entrada Therapeutics is a clinical-stage biopharmaceutical company leveraging its proprietary Endosomal Escape Vehicle (EEV™) platform to deliver intracellular genetic medicines. The company's primary focus is on its Duchenne muscular dystrophy (DMD) franchise, which targets exons 44, 45, 50, and 51. Early clinical data from the ELEVATE-44-201 study (Cohort 1) demonstrated favorable safety and statistically significant functional improvements (Time to Rise velocity), validating the platform's potential. Backed by a strong cash position of $254.9M (as of Q1 2026) providing a runway into Q3 2027, and a high-value clinical partnership with Vertex Pharmaceuticals for myotonic dystrophy type 1 (DM1), Entrada offers an attractive risk-reward profile for speculative biotech investors.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets4 analysts · as of 18 Aug 2026

Low · most bearish analyst$10.00

Mean target$18.75

High · most bullish analyst$25.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$10.0020%

The bear case is triggered by safety concerns or lack of dose-dependent efficacy in higher-dose cohorts (such as renal toxicity or insufficient dystrophin production). Delays in regulatory approvals for EU trials of ENTR-601-50 or global trials of ENTR-601-51 stall pipeline momentum. If Vertex's DM1 trial (VX-670) encounters safety hurdles, the platform's validation is compromised, leading to rapid cash burn and a depressed valuation that forces highly dilutive capital raises.

Base CaseCentral scenario

$18.7550%

Matches the consensus mean

The base case assumes steady clinical execution. ENTR-601-44 Cohort 2 and ENTR-601-45 Cohort 1 readouts in 2026 demonstrate clear dose-dependent exon skipping and acceptable safety profiles, supporting progression to higher-dose cohorts. Regulatory filings for ENTR-601-50 and ENTR-601-51 proceed on schedule. The cash runway remains secure into Q3 2027, allowing the company to generate robust proof-of-concept data before requiring additional dilutive financing.

Bull CaseUpside scenario

$25.0030%

The bull case assumes outstanding clinical success across the DMD franchise. Cohort 2 (12 mg/kg) of ENTR-601-44 achieves double-digit dystrophin expression by year-end 2026, confirming NHP-based translation models. Efficacy is mirrored in the ENTR-601-45 and ENTR-601-50 programs, establishing Entrada's EEV platform as the best-in-class delivery mechanism for oligonucleotide therapeutics. Vertex successfully advances VX-670, triggering substantial milestone payments. The company's valuation expands rapidly as it transitions toward pivotal trials.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Proprietary EEV™ platform achieves up to 50% endosomal escape, significantly improving intracellular delivery efficiency over conventional biologics.
Statistically significant functional benefit (Time to Rise velocity) observed early in ELEVATE-44-201 Cohort 1, despite low-dose levels.
Strong balance sheet with $254.9M in cash and marketable securities, funding operations into Q3 2027.
Strategic partnership with Vertex Pharmaceuticals for DM1 (VX-670) provides external validation and potential milestone inflows.

Key Investment Risks

High clinical-stage risk; failure to show dose-dependent dystrophin increases in higher cohorts would severely impact the DMD franchise.
Intense competition in the DMD space from established players like Sarepta Therapeutics and clinical-stage peers like Avidity Biosciences and Dyne Therapeutics.
Pre-revenue status means the company is entirely dependent on capital markets or partnership milestones to sustain its high R&D burn rate.

Thesis Invalidation Triggers

Emergence of severe adverse events (e.g., severe renal toxicity) in ELEVATE-44-201 Cohort 2 or ELEVATE-45-201 trials.
Failure of ENTR-601-44 Cohort 2 to show a meaningful increase in dystrophin expression compared to Cohort 1.
Termination or significant delay of the VX-670 myotonic dystrophy type 1 program by partner Vertex.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.